WAILEA, Hawaii — Considering bevacizumab was found to be noninferior to aflibercept with respect to visual acuity in the SCORE2 trial, the incremental cost-effectiveness ratio is “unfavorable,” Michael S. Ip, MD, said at Retina 2021.
“The mathematics are fairly straightforward,” Ip said. “The 12-month differences are about $18,000 between bevacizumab and aflibercept groups, and the differences in quality of adjusted life-years ... are very small.”
The SCORE2 included 362 patients with macular edema associated with central or hemi-retinal vein occlusion